at-527
Small moleculeexperimentalCOVID-19
Clinical trial activity
24 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
18
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Jul 6, 2017 (NCT03219957)
Timeline
Indications
Mechanism of action
- Molecular identity unknownINHIBITOR
Molecular identity unknown inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc2ccccc2)[C@@H](O)[C@@]1(C)F- Mol. weight
- 581.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL5095404 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06356194 | Phase 1 | Apr 15, 2024 | Atea Pharmaceuticals, Inc. |
| NCT05905497 | Phase 1 | Apr 26, 2023 | Atea Pharmaceuticals, Inc. |
| NCT05905484 | Phase 1 | Apr 25, 2023 | Atea Pharmaceuticals, Inc. |
| NCT05724693 | Phase 1 | Jan 30, 2023 | Atea Pharmaceuticals, Inc. |
| NCT05731843 | Phase 1 | Jan 30, 2023 | Atea Pharmaceuticals, Inc. |
| NCT05629962 | Phase 3 | Nov 25, 2022 | Atea Pharmaceuticals, Inc. |
| NCT05618314 | Phase 1 | Oct 17, 2022 | Atea Pharmaceuticals, Inc. |
| NCT05293028 | Phase 1 | May 20, 2022 | Shandong New Time Pharmaceutical Co., LTD |
| NCT05256732 | Phase 1 | Feb 22, 2022 | Atea Pharmaceuticals, Inc. |
| NCT05137626 | Phase 1 | Nov 30, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT05154123 | Phase 1 | Nov 16, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT05004415 | Phase 1 | Jul 28, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT05126576 | Phase 3 | Apr 28, 2021 | Roche |
| NCT04889040 | Phase 3 | Apr 28, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04877769 | Phase 1 | Apr 25, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04865445 | Phase 1 | Apr 22, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04849299 | Phase 1 | Apr 18, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04784000 | Phase 1 | Mar 1, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04709835 | Phase 2 | Feb 3, 2021 | Atea Pharmaceuticals, Inc., Roche |
| NCT04711187 | Phase 1 | Nov 2, 2020 | Atea Pharmaceuticals, Inc., Roche |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | For profit | 22 | 21 | 3 | 2017 |
| Roche | For profit | 11 | 2 | 3 | 2020 |
| Shandong New Time Pharmaceutical Co., LTD | Government | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1